What is Motilat?
Motilat is a medicine that increases the movements or contractions of the stomach and bowel. Motilat is also used to treat nausea and vomiting caused by other drugs used to treat Parkinson's Disease.
Motilat is to be given only by or under the immediate supervision of your doctor.
Motilat indications
Dyspeptic symptom complex often associated with delayed gastric emptying, gastroesophageal reflux disease (GERD) or esophagitis: Epigastric sense of fullness, feeling of abdominal distention, upper abdominal pain, flatulence (gassiness), eructation (belching), and heartburn.
Short-term treatment of nausea and vomiting of various origins including functional, organic, infectious, diabetic origin, or induced by radiotherapy or medicine therapy. (It is not considered suitable for chronic nausea and vomiting, nor for the routine prophylaxis of postoperative vomiting.)
Treatment of nausea and vomiting induced by dopamine agonists ie, L-dopa and bromocriptine used in Parkinson's disease.
Motilat may also be given as needed, together with paracetamol for the symptomatic treatment of nausea and vomiting associated with migraine.
Uses of Motilat in details
Motilat is used to treat vomiting or nausea caused due to indigestion, diseases or drugs. It is also used to relieve fullness of stomach, belching and heavy bloating, gas and heartburn for a longer period up to 2 weeks.
Motilat description
Motilat is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K mediated gamma-carboxylation of precursor proteins.
Motilat dosage
It is recommended to take oral Motilat before meals. If taken after meals, absorption of the drug is somewhat delayed.
Adults and Adolescents >12 years and weighing ≥35 kg: Tablets: One to two 10-mg tablet 3-4 times/day, with a maximum daily dose of 8 tablets (80 mg).
Oral Suspension:
10-20 mL (of oral susp containing Motilat 1 mg/mL) 3-4 times/day, with a maximum daily dose of 80 mL.Infants and Children: 0.25-0.5 mg/kg 3-4 times/day with a maximum daily dose of 2.4 mg/kg (but do not exceed 80 mg/day).
Tablets are unsuitable for use in children weighing <35 kg.
Oral Suspension:
0.25-0.5 mg/kg 3-4 times/day with a maximum dose of 2.4 mg/kg (not exceeding 80 mL).Motilat interactions
The concomitant administration of Motilat with phenothiazines, butyrophenones and rauwolfia alkaloids may induce the endocrine disturbances or extrapyramidal disorders. If necessary, monitored carefully and administered cautiously.
Should be administered cautiously in patients receiving digitalis preparations.
The concomitant administration of Motilat with anticholinergic agents may compromise the beneficial effects of Motilat because of depressing the promoting action of gastrointestinal motility.
Theologically, Motilat may have an effect on the absorption of oral preparations, especially slow-releasing or enteric-coated preparations because of increasing gastric motility. But in patients stabilized with digoxin or acetaminophen, the concomitant administration of Motilat had no effect on plasma concentration of these drugs.
It is not reported that Motilat enhances the effect of neuroleptics.
Motilat inhibits peripheral adverse reactions eg, dyspepsia, nausea, vomiting, induced by dopamine agonist (eg, bromocriptine, levodopa), but has no effect on central nervous system.
As the concomitant administration of Motilat with antacids or acid secretion inhibitors lowers biologic activity of Motilat, these drugs should not be used together.
The actions of Motilat on gastrointestinal function may be antagonised by antimuscarinics and opioid analgesics.
Motilat side effects
See also:
What are the possible side effects of Motilat?
Clinical Trial Data: The safety of Motilat was evaluated in 1221 patients with gastroparesis, dyspepsia, gastro-oesophageal reflux disorder (GERD) or other related conditions in 45 clinical trials included in the safety database. All patients were ≥15 years and received at least 1 dose of oral Motilat (Motilat base). Slightly fewer than one-half (553/1221) of patients were diabetic. The median total daily dose was 80 mg (range 10-160 mg), with 230 patients receiving a dose >80 mg. Median duration of exposure was 56 days (range 1-2248 days).
Adverse drug reactions (ADRs) reported by ≥1% of patients treated with oral Motilat in these 45 clinical trials (n=1221) are the following: Psychiatric Disorders: Depression (2.5%), anxiety (1.6%), decreased libido/loss of libido (1.5%).
Nervous System Disorders: Headache (5.6%), somnolence (2.5%), akathisia (1%).
Gastrointestinal Disorders: Diarrhoea (5.2%).
Skin and Subcutaneous Tissue Disorders: Rash (2.8%), pruritus (1.7%).
Reproductive System and Breast Disorders: Breast enlargement/gynaecomastia (5.3%), breast tenderness (4.4%), galactorrhoea (3.3%), amenorrhoea (2.9%), breast pain (2.3%), irregular menstruation (2%), lactation disorder (1.6%).
General Disorders and Administration Site Conditions: Asthenia (1.9%).
ADRs that occurred in <1% of Motilat-treated patients in the 45 clinical trials (n=1221) are the following: Immune System Disorders: Hypersensitivity (0.2%).
Skin and Subcutaneous Disorders: Urticaria (0.7%).
Reproductive System and Breast Disorders: Breast discharge (0.8%), breast swelling (0.5%).
Dry mouth has been reported with over-the-counter use of Motilat.
Post-Marketing: In addition to the adverse effects reported during clinical studies and previously mentioned, the following adverse drug reactions provided the frequencies according to the following convention: Very common (≥1/10), common (≥1/100 and <1/10); uncommon (≥1/1000 and <1/100); rare (≥1/10,000 and <1/1000); very rare (<1/10,000, including isolated reports).
The following ADRs are presented by frequency category based on spontaneous reporting rates: Immune System Disorders: Very Rare: Anaphylactic reactions (including anaphylactic shock).
Psychiatric Disorders: Very Rare: Agitation, nervousness.
Nervous System Disorders: Very Rare: Extrapyramidal disorder, convulsion.
Cardiac Disorders: Very Rare: Sudden cardiac death*, serious ventricular arrhythmias*.
Skin and Subcutaneous Tissue Disorders: Very Rare: Angioedema.
Renal and Urinary Disorders: Very Rare: Urinary retention.
Investigations: Very Rare: Abnormal liver function test; increased blood prolactin.
Note: *Based on epidemiology data (as follows).
As the hypophysis is outside the blood-brain barrier, Motilat may cause an increase in prolactin levels. In rare cases, this hyperprolactinaemia may lead to neuro-endocrinological side effects eg, galactorrhoea, gynaecomastia and amenorrhoea.
Extrapyramidal disorder occurs primarily in neonates and infants.
Other central nervous system-related effects of convulsion and agitation are also reported primarily in infants and children.
An increase in the risk of serious ventricular arrhythmias and sudden cardiac death has been reported in some epidemiology studies. Due to the limitations of these data, risk factors and the exact frequency of these adverse reactions could not be defined.
Motilat contraindications
Hypersensitivity to Motilat or any ingredient of Motilat.
If patients are taking oral ketoconazole, fluconazole, voriconazole, erythromycin, clarithromycin, telithromycin, amiodarone, selective serotonin reuptake inhibitors, HIV protease inhibitors, calcium antagonists which can increase plasma concentrations of Motilat, leading to a prolonged QTc interval. These medicines can increase plasma concentrations of Motilat leading to a prolonged QTc interval. Patients with long QT syndrome develop a very fast heart rhythm disturbance leading to a sudden loss of consciousness.
Gastrointestinal hemorrhage (bleeding), obstruction, perforation or conditions where gastrointestinal stimulation or movements may be dangerous.
Prolactin-releasing pituitary tumor (prolactinoma).
Active ingredient matches for Motilat:
Domperidone in Oman.
List of Motilat substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Motilar (Thailand) | |
| Motilar 1 mg/1 mL x 3, 750 mL (Rowe-fleming) | |
| Motilat 10mg (Oman) | |
| Motilat suspension | |
| Motilex (Bangladesh, Indonesia, Italy) | |
| Motilex 2 mg x 100's (Kalbe Farma) | $ 13.64 |
| Motilidone (Canada) | |
| Tablet; Oral; Domperidone Maleate 10 mg (Technilab) | |
| Motilidone tablet 10 mg (Technilab) | |
| Motilin (Thailand) | |
| Motilin 10 mg x 1, 000's | |
| Motilin 10 mg x 500's | |
| Motilin 1 mg/1 mL x 30 mL | |
| Motilin 1 mg/1 mL x 60 mL | |
| Motilin 1 mg/1 mL x 100 mL | |
| Motilin 1 mg/1 mL x 3, 750 mL | |
| Motiliosyr 1 | |
| Motilite (Pakistan) | |
| Motilium (Algeria, Antigua & Barbuda, Argentina, Aruba, Australia, Austria, Bahamas, Barbados, Belgium, Benin, Bermuda, Brazil, Burkina Faso, Cameroon, Cayman Islands, Central African Republic, Chad, China, Congo, Costa Rica, Cote D'ivoire, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, France, Gabon, Georgia, Germany, Grenada, Guatemala, Guinea, Guyana, Honduras, Hong Kong, Hungary, Indonesia, Ireland, Israel, Italy, Jamaica, Jordan, Latvia, Lebanon, Lithuania, Luxembourg, Madagascar, Malaysia, Mali, Malta, Mauritania, Mexico, Myanmar, Netherlands, Netherlands Antilles, New Zealand, Nicaragua, Niger, Oman, Panama, Peru, Philippines, Portugal, Romania, Russian Federation, Saint Lucia, Saint Vincent & The Grenadines, Saudi Arabia, Senegal, Singapore, South Africa, Spain, Sri Lanka, Sudan, Suriname, Switzerland, Taiwan, Thailand, Togo, Trinidad & Tobago, Tunisia, Turkey, United Arab Emirates, United Kingdom, Vietnam, Yemen) | |
| Granules, Effervescent; Oral; Domperidone 10 mg (Janssen) | |
| Suppositories; Rectal; Domperidone 10 mg (Janssen) | |
| Suppositories; Rectal; Domperidone 30 mg (Janssen) | |
| Suppositories; Rectal; Domperidone 60 mg (Janssen) | |
| Suspension; Oral; Domperidone 5 mg / 5 ml (Janssen) | |
| Tablet, Film-Coated; Oral; Domperidone 10 mg (Janssen) | |
| Tablet, Orally Disintegrating; Oral; Domperidone 10 mg (Janssen) | |
| Tablet; Oral; Domperidone 10 mg (Janssen) | |
| Motilium - 30 Tablets (Janssen) | $ 16.70 |
| Motilium 10 mg x 100's (Janssen) | $ 55.82 |
| Motilium 1 mg/1 mL x 200 mL (Janssen) | $ 205.00 |
| Motilium 1 mg/1 mL x 30 mL (Janssen) | |
| Motilium -M 10 mg x 50 x 10's (Janssen) | |
| Motilium 1 mg/1 mL x 60 mL (Janssen) | $ 8.38 |
| Motilium 10 mg x 500's (Janssen) | |
| Motilium 1 mg/1 mL x 200 mL x 1's (Janssen) | |
| Motilium 10 mg x 50's (Janssen) | $ 20.44 |
| Motilium 1 mg/1 mL x 60 mL x 1's (Janssen) | $ 5.08 |
| Motilium oral susp 1 mg/mL 100 mL x 1's (Janssen) | $ 9.51 |
| Motilium tab 10 mg 500's (Janssen) | |
| Motilium film-coated tab 10 mg 100's (Janssen) | $ 61.60 |
| Motilium syr 1 mg/mL 200 mL x 1's (Janssen) | $ 205.00 |
| Motilium film-coated tab 10 mg 500's (Janssen) | |
| Motilium oral susp 1 mg/mL 200 mL x 1's (Janssen) | |
| Motilium 10 (United Kingdom) | |
| Motilium 10mg (Austria, Hungary, Luxembourg, Oman, Switzerland) | |
| Motilium 1mg/ml (Austria, Luxembourg, Oman, Switzerland) | |
| Motilium Babies | |
| Suppositories; Rectal; Domperidone 10 mg | |
See 2682 substitutes for Motilat | |
References
- PubChem. "domperidone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "domperidone". http://www.drugbank.ca/drugs/DB01184 (accessed September 17, 2018).
- DTP/NCI. "domperidone: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Motilat are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Motilat. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
3 consumers reported useful
Was the Motilat drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
| Users | % | ||
|---|---|---|---|
| Useful | 2 | 66.7% | |
| Not useful | 1 | 33.3% | |
Consumer reported price estimates
No survey data has been collected yet5 consumers reported time for results
To what extent do I have to use Motilat before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Motilat. To get the time effectiveness of using Motilat drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| 1 day | 2 | 40.0% | |
| 2 weeks | 1 | 20.0% | |
| 1 month | 1 | 20.0% | |
| 1 week | 1 | 20.0% | |
14 consumers reported age
| Users | % | ||
|---|---|---|---|
| 1-5 | 6 | 42.9% | |
| < 1 | 3 | 21.4% | |
| 6-15 | 2 | 14.3% | |
| 16-29 | 1 | 7.1% | |
| 46-60 | 1 | 7.1% | |
| 30-45 | 1 | 7.1% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
